All In Biotech

Drug Trial Radar · NCT05653856

Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer

A Multi-Center, Open-Label, Randomized Phase 2 Study of Copper Cu 64 PSMA I&T Injection in Patients With Histologically Proven Metastatic Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Jan 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

26

Actual

Start

Dec 5, 2022

Primary completion

May 17, 2023

Study completion May 17, 2023

Sponsor

Lead sponsor
Curium US LLCIndustry
Sponsor type
Industry
First posted
Dec 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label Phase 2 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent metastatic prostate cancer after radical prostatectomy or radiation therapy.

Conditions

  • Metastasis From Malignant Tumor of Prostate (Disorder)

Interventions

  • 64Cu-PSMA I&TDrug

    Radiolabeled Receptor-Targeted Diagnostic Product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Region-Level Correct Localization Rate (CLR)Time frame: 4 Hours
  2. Patient-Level Correct Detection Rate (CDR)Time frame: 4 Hours
  3. Incidence of Adverse EventsTime frame: 24 Hours

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Yale University

    New Haven, Connecticut

  • Edward Hines, Jr. VA Hospital

    Hines, Illinois

  • Johns Hopkins University

    Baltimore, Maryland

  • Saint Louis University

    St Louis, Missouri

  • John J. Cochran Veterans Hospital

    St Louis, Missouri

  • Washington University

    St Louis, Missouri

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • XCancer Omaha/Urology Cancer Center

    Omaha, Nebraska

  • MD Anderson

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.